CD274 and non-small cell lung carcinoma: While ICI monotherapy can spare patients from the devastating side effects of chemotherapy, only ~15% of NSCLC patients truly benefit from it, given that 23.2–30.2% of NSCLC patients have a PD-L1 TPS ≥ 50% [3,4,11].